Premium
PROTACs and Other Chemical Protein Degradation Technologies for the Treatment of Neurodegenerative Disorders
Author(s) -
Tomoshige Shusuke,
Ishikawa Minoru
Publication year - 2021
Publication title -
angewandte chemie international edition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 1433-7851
DOI - 10.1002/anie.202004746
Subject(s) - protein degradation , drug discovery , drug , protein aggregation , degradation (telecommunications) , neuroscience , computational biology , chemistry , bioinformatics , medicine , pharmacology , biology , microbiology and biotechnology , computer science , telecommunications
Neurodegenerative disorders (NDs) are a group of diseases that cause neural cell damage, leading to motility and/or cognitive dysfunctions. One of the causative agents is misfolded protein aggregates, which are considered as undruggable in terms of conventional tools, such as inhibitors and agonists/antagonists. Indeed, there is currently no FDA‐approved drug for the causal treatment of NDs. However, emerging technologies for chemical protein degradation are opening up the possibility of selective elimination of target proteins through physiological protein degradation machineries, which do not depend on the functions of the target proteins. Here, we review recent efforts towards the treatment of NDs using chemical protein degradation technologies, and we briefly discuss the challenges and prospects.